MétaCan
Menu
Back to cohort

Abstract P6-05-07: Discordance in estrogen receptor, progesterone receptor and HER-2/neu status between primary and metastatic breast cancer: A systematic review

2013· review· en· W2027306043 on OpenAlexaff
I. Ching Yeung, M. Clemons, Fatima Haggar, Christina Addison, B Hutton, Iryna Kuchuk, Xudong Zhu, Sasha Mazzarello, Angel Arnaout

Bibliographic record

VenueCancer Research · 2013
Typereview
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsOttawa HospitalUniversity of Ottawa
Fundersnot available
KeywordsMedicineOncologyBreast cancerMetastatic breast cancerInternal medicineEstrogen receptorInterquartile rangeGynecologyCancerProgesterone receptorMetastasis

Abstract

fetched live from OpenAlex

Abstract BACKGROUND AND OBJECTIVE Systemic treatment choices for metastatic breast cancer are based, in part, on the estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor (HER2) status of the primary cancer. Receptor discordance between primary and associated metastases is well recognized and could have important therapeutic implications. A systematic review of all relevant studies was conducted to assess the extent of discordance in ER, PR and HER2 status between primary breast cancers and their paired metastases. METHODS A search was performed using EMBASE (1980-2013), Medline (1966-2013) and Cochrane Central Register of Controlled Trials (CENTRAL, 2013 issue 1), references of included studies, relevant review articles and conference abstracts. Only English-language cohort studies reporting ER, PR, and HER2 expression for matching primary breast cancer and metastatic sites were eligible. Title and abstract screening was performed by one reviewer; full text articles of potentially relevant citations were independently screened by two reviewers. Using pre-defined criteria, two reviewers performed data extraction of the included studies, as well as methodologic quality assessment (QUADAS-2) and risk of bias assessment. Disagreements by reviewers were adjudicated by consensus. Median discordance and interquartile range (IQR) of discordance of each of the biomarkers (ER, PR, HER2) between primary breast cancer and their paired metastases were calculated. Association between receptor discordance and site of metastasis site was also explored. RESULTS Of the 5034 citations identified, 58 studies (representing a total of 3,522 matched primary and metastatic pairs) met our inclusion criteria. Studies were generally small, as reflected by the median number of matched pairs of 42 (range 4-370). Median discordance rates between primary and paired metastases were 18% (IQR10–29%) for ER, 23% (IQR16–43%) for PR and 9% (IQR 4–14%) for HER2 respectively. Discordance rates were higher if the metastatic site was a lymph node [ER: 42% (42–60%); PR: 48% (46–50%); HER2: 25% (11–38%)] as compared to all other sites of disease (e.g. bone marrow, lung, liver and brain) [ER: 25% (14-42%); PR: 36%(19-45)%; HER2: 13% (5-21%)]. Overall, receptor loss was more common than receptor gain across all metastatic sites. CONCLUSION This is the first systematic review we are aware of, that evaluates the extent, direction, and relationship of ER, PR and HER2 discordance between primary breast cancer and their paired metastases. Discordance varied from 10-60% depending on the receptor type and site of metastasis. When discordance occurs, loss of a biomarker is most common and most frequent with PR. These results could have important therapeutic implications in the treatment of recurrent and metastatic breast cancer. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-05-07.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Research integrity
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.398
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0070.000
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0000.001
Open science0.0010.000
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.120
GPT teacher head0.450
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207